Default Category
-
Tale of Two Electronic Components Distributors (Spanish Version)
Raman, Ananth; Rao, Bharat P.Case HBS-604S15Service and Operations ManagementDiscute el papel de los intermediarios de distribución en la industria de componentes electrónicos, y describe las operaciones en dos de estos distribuidores. Sirve como un vehículo para discutir las funciones proporcionadas por los distribuidores en el canal. También permite a los estudiantes a entender las diferencias entre los distribuidores y discutir cómo cada uno de ellos va a hacer frente a cuestiones como la consolidación y el rápido crec...Starting at €8.20
-
Improving the Patient Experience (Spanish version)
Raman, Ananth; Tucker, AnitaCase HBS-615S02Service and Operations ManagementHealthcare has traditionally focused on medical outcomes and financial performance. The big question is always, "How much is it going to cost?" What would happen, though, if healthcare also considered the question of "How does the patient feel?" This case looks at the Cleveland Clinic's attempt to answer the latter question by attempting to institutionalize empathy as part of its delivery of care.Starting at €8.20
-
Accounting Fraud at WorldCom (Spanish version)
Kaplan, Robert S.; Kiron, DavidCase HBS-109S04Business Ethics and Corporate Social ResponsibilityThe principal players in WorldCom's accounting fraud included CFO Scott Sullivan, the General Accounting and Internal Audit departments, external auditor Arthur Andersen, and the board of directors. The case provides sufficient detail to allow for a full discussion of the pressures that lead executives and managers to "cook the books," the boundary between earnings smoothing or management and fraudulent reporting, the role for internal control sy...Starting at €8.20
-
Merck: Investing in Science-Based Business (Abridged)
Raman, Ananth; Maurer, IngaCase HBS-611027-EService and Operations ManagementRay Gilmartin faces a dilemma. His company's credibility has been damaged by the recent withdrawal of Vioxx, a multi-billion dollar drug. Moreover, the withdrawal of Vioxx would imply that Merck would fail to meet analysts' earnings expectations for 2005 unless Gilmartin cuts the R&D budget. Cutting the budget might hurt morale and productivity in Merck labs.Starting at €8.20
-
Cleveland Clinic: Improving the Patient Experience
Raman, Ananth; Tucker, AnitaCase HBS-612031-EService and Operations ManagementHealthcare has traditionally focused on medical outcomes and financial performance. The big question is always, "How much is it going to cost?" What would happen, though, if healthcare also considered the question of "How does the patient feel?" This case looks at the Cleveland Clinic's attempt to answer the latter question by attempting to institutionalize empathy as part of its delivery of care.Starting at €8.20
-
Merck: Operating Science-Based Business
Raman, Ananth; Maurer, Inga; Schmidt, WilliamCase HBS-612082-EService and Operations ManagementMerck is known for its commitment to investing in basic R&D. Are Merck's long-term investments justifiable when the firm faces extreme earnings pressure?Starting at €8.20
-
SCMS: Battling HIV/AIDS in Africa
Raman, Ananth; Watson, Noel; Kraiselburd, Santiago; Akili, EmmanuelCase HBS-613023-EService and Operations ManagementIn 2005, USAID and the U.S. President s Emergency Plan for AIDS Relief (PEPFAR), created the Supply Chain Management System (SCMS) to procure and distribute essential medicines and supplies; provide technical assistance to transform existing supply chains; and collaborated with in-country and global partners to coordinate efforts. The new US Global Health Initiative (GHI) initialized in 2010 sought to build on these efforts through strengthened ...Starting at €8.20
-
MINTing Innovation at NewYork-Presbyterian (A) and (B), Teaching Note
Hamermesh, Richard G.; Kiron, DavidTeaching Note HBS-811010-EEntrepreneurshipTeaching Note for 810004.Starting at €0.00
-
Gene Patents (A)
Hamermesh, Richard G.; Kiron, David; Andrews, PhillipCase HBS-811089-EEntrepreneurshipIn March 2010, U.S. District Court Judge Robert Sweet overturned 30 years of legal precedent and ruled that unaltered human genes could not be patented. This case reviews patent law and how it relates to our increasing knowledge of the Human Genome. The case issues deal with the potential implications of Judge Sweet's decision for biotechnology entrepreneurs and investors.Starting at €8.20
-
MINTing Innovation at NewYork-Presbyterian (A)
Hamermesh, Richard G.; Kiron, DavidCase HBS-810004-EEntrepreneurshipSeveral top surgeons at NewYork-Presbyterian hospital (NYP) are receiving financial and administrative support to advance their surgical device inventions through the earliest stages of commercialization.Starting at €8.20